title: Simulation Model of Ibrutinib for Chronic Lymphocytic Leukemia (CLL) With Prior Treatment.
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: F
authors.initials: F
authors.lastname: Pan
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Peng
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Sorensen
authors.affiliation: Evidera, Bethesda, MD, USA.
authors.forename: E
authors.initials: E
authors.lastname: Dorman
authors.affiliation: Janssen, Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ, USA.
authors.forename: S
authors.initials: S
authors.lastname: Sun
authors.affiliation: Janssen Pharmaceuticals, Inc, Neuss, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Gaudig
authors.affiliation: Janssen Pharmaceuticals, Inc, Raritan, NJ, USA.
authors.forename: N
authors.initials: N
authors.lastname: Sengupta